Dentalcare-aus The trusted resource for dental professionals

Pharmacology of Selected Therapeutic Agents in Oral Medicine
References / Additional Resources

Course Author(s): David Leonard Ojeda Diaz, DDS; Michaell A. Huber, DDS

References

  1. Miranda-Rius J, Brunet-Llobet L, Lahor-Soler E, et al. Salivary Secretory Disorders, Inducing Drugs, and Clinical Management. Int J Med Sci. 2015 Sep 22;12(10):811-24. doi: 10.7150/ijms.12912. eCollection 2015.
  2. Bowers LM, Fox PC, Brennan MT. Salivary gland disease. Burket’s oral medicine 12th ed. Connecticut, USA. People’s Medical Publishing House. 2015. p. 219-262.
  3. Villa A, Wolff A, Narayana N, et al. World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction. Oral Dis. 2016 Jul;22(5):365-82. doi: 10.1111/odi.12402. Epub 2016 Jan 20.
  4. Plemons JM, Al-Hashimi I, Marek CL, et al. Managing xerostomia and salivary gland hypofunction: executive summary of a report from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2014 Aug;145(8):867-73. doi: 10.14219/jada.2014.44.
  5. Hillman C, Terezhalmy G. Saliva: Liquid Magic. dentalcare.com. Accessed April 4, 2018.
  6. Hovious M. Caries Process and Prevention Strategies. dentalcare.com. Accessed April 4, 2018.
  7. Saleh J, Figueiredo MA, Cherubini K, et al. Salivary hypofunction: an update on aetiology, diagnosis and therapeutics. Arch Oral Biol. 2015 Feb;60(2):242-55. doi: 10.1016/j.archoralbio.2014.10.004. Epub 2014 Nov 4.
  8. FDA. Pilocarpine Package Insert. Accessed April 4, 2018.
  9. FDA. Cevimeline Package Insert. Accessed April 4, 2018.
  10. Cui RZ, Bruce AJ, Rogers RS 3rd. Recurrent aphthous stomatitis. Clin Dermatol. 2016 Jul-Aug;34(4):475-81. doi: 10.1016/j.clindermatol.2016.02.020. Epub 2016 Mar 2.
  11. Mimura MA, Hirota SK, Sugaya NN, et al. Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial. Clinics (Sao Paulo). 2009;64(3):193-8.
  12. The Prescriber’s Letter. PL Detail-Document, Prevention and Treatment of Oral Mucositis. Pharmacist’s Letter/Prescriber’s Letter. November 2014. Accessed April 4, 2018.
  13. Stoopler ET, Sollecito TP. Oral mucosal diseases: evaluation and management. Med Clin North Am. 2014 Nov;98(6):1323-52. doi: 10.1016/j.mcna.2014.08.006. Epub 2014 Sep 22.
  14. Akintoye SO, Greenberg MS. Recurrent aphthous stomatitis. Dent Clin North Am. 2014 Apr;58(2):281-97. doi: 10.1016/j.cden.2013.12.002. Epub 2014 Jan 21.
  15. Samim F, Auluck A, Zed C, et al. Erythema multiforme: a review of epidemiology, pathogenesis, clinical features, and treatment. Dent Clin North Am. 2013 Oct;57(4):583-96. doi: 10.1016/j.cden.2013.07.001.
  16. Celentano A, Tovaru S, Yap T, et al. Oral erythema multiforme: trends and clinical findings of a large retrospective European case series. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Dec;120(6):707-16. doi: 10.1016/j.oooo.2015.08.010. Epub 2015 Aug 22.
  17. Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, et al. Current Perspectives on Erythema Multiforme. Clin Rev Allergy Immunol. 2018 Feb;54(1):177-184. doi: 10.1007/s12016-017-8667-7.
  18. Balasubramaniam R, Kuperstein AS, Stoopler ET. Update on oral herpes virus infections. Dent Clin North Am. 2014 Apr;58(2):265-80. doi: 10.1016/j.cden.2013.12.001.
  19. Huber MA. Oral lichen planus. Quintessence Int. 2004 Oct;35(9):731-52.
  20. Kurago ZB. Etiology and pathogenesis of oral lichen planus: an overview. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Jul;122(1):72-80. doi: 10.1016/j.oooo.2016.03.011. Epub 2016 Mar 19.
  21. Aghbari SMH, Abushouk AI, Attia A, et al. Malignant transformation of oral lichen planus and oral lichenoid lesions: A meta-analysis of 20095 patient data. Oral Oncol. 2017 May;68:92-102. doi: 10.1016/j.oraloncology.2017.03.012. Epub 2017 Apr 5.
  22. Payeras MR, Cherubini K, Figueiredo MA, et al. Oral lichen planus: focus on etiopathogenesis. Arch Oral Biol. 2013 Sep;58(9):1057-69. doi: 10.1016/j.archoralbio.2013.04.004. Epub 2013 May 6.
  23. Olson MA, Rogers RS 3rd, Bruce AJ. Oral lichen planus. Clin Dermatol. 2016 Jul-Aug;34(4):495-504. doi: 10.1016/j.clindermatol.2016.02.023. Epub 2016 Mar 2.
  24. Farhi D, Dupin N. Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: facts and controversies. Clin Dermatol. 2010 Jan-Feb;28(1):100-8. doi: 10.1016/j.clindermatol.2009.03.004.
  25. Siponen M, Huuskonen L, Kallio-Pulkkinen S, et al. Topical tacrolimus, triamcinolone acetonide, and placebo in oral lichen planus: a pilot randomized controlled trial. Oral Dis. 2017 Jul;23(5):660-668. doi: 10.1111/odi.12653. Epub 2017 Mar 31.
  26. Sultan AS, Villa A, Saavedra AP, et al. Oral mucous membrane pemphigoid and pemphigus vulgaris-a retrospective two-center cohort study. Oral Dis. 2017 May;23(4):498-504. doi: 10.1111/odi.12639. Epub 2017 Feb 22.
  27. Urbano F. Nikolsky’s sign in autoimmune skin disorders. Hospital Physician 2001;37:23-24. Accessed April 4, 2018.
  28. Cholera M, Chainani-Wu N. Management of Pemphigus Vulgaris. Adv Ther. 2016 Jun;33(6):910-58. doi: 10.1007/s12325-016-0343-4. Epub 2016 Jun 10.

Additional Resources

  • No Additional Resources Available
Print